1 / 23

Drug-eluting or absorbable stents versus bare-metal stents in peripheral artery disease

Drug-eluting or absorbable stents versus bare-metal stents in peripheral artery disease. Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com. Scope of the problem. Biondi Zoccai et al, G Ital Cardiol 2009. Scope of the problem - II.

chenoa
Télécharger la présentation

Drug-eluting or absorbable stents versus bare-metal stents in peripheral artery disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug-eluting or absorbable stents versus bare-metal stents in peripheral artery disease Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino gbiondizoccai@gmail.com

  2. Scope of the problem Biondi Zoccai et al, G ItalCardiol 2009

  3. Scope of the problem - II

  4. Scope of the problem - III

  5. TASC II 2007 vs. TASC 2000

  6. Why stents? • Balloon-only angioplasty is fraught with: • Elastic recoil • Flow-limiting dissection • Constrictive remodeling • Neointimal hyperplasia • Biocompatibility • Stents may address these issues

  7. Why stents? • Balloon-only angioplasty is fraught with: • Elastic recoil • Flow-limiting dissection • Constrictive remodeling • Neointimal hyperplasia • Biocompatibility • Stents may address these issues BMS

  8. Why stents? • Balloon-only angioplasty is fraught with: • Elastic recoil • Flow-limiting dissection • Constrictive remodeling • Neointimal hyperplasia • Biocompatibility • Stents may address these issues DES

  9. Why stents? • Balloon-only angioplasty is fraught with: • Elastic recoil • Flow-limiting dissection • Constrictive remodeling • Neointimal hyperplasia • Biocompatibility • Stents may address these issues ABS

  10. Explosion of data on stents for PAD PubMed queried on 7 December 2009: stent* AND (femoral OR popliteal OR femoropopliteal OR "femoro-popliteal" OR tibial OR "infra-popliteal" OR infrapopliteal OR (critical AND limb AND ischemia)) NOT (vein OR venous)

  11. Iliac stenting: just in bail-out? DutchIliacStent Trial: randomized trial of stenting vs balloon-only PTA (withstentifcomplications or meangradient >10 mm Hg)* *stentingfinallyperformed in 40% ofptsrandomizedto PTA Routine stenting PTA with selective stenting Klein et al, Radiology 2006

  12. The FAST trial: Luminexx stent

  13. The ABSOLUTE trial: Absolute stent Schillinger et al, Circulation 2007

  14. The RESILIENT II trial: LifeStent12-month results

  15. Can you beat new bare-metal stents?

  16. The SIROCCO I trial: Sirolimus-eluting Smart stent Duda et al, Circulation 2002

  17. The SIROCCO II trial: Sirolimus-eluting Smart stentFreedom from restenosis 71.8% 67.2% Duda et al, J VascIntervRadiol 2005

  18. Zilver paclitaxel eluting stent

  19. Repeat PTA after BTK stenting Biondi-Zoccai et al, J EndovascTher 2009

  20. What about absorbable stents? BASELINE 6 MONTHS POST-AMS Bosiers et al, CardiovascInterventRadiol 2009

  21. What about absorbable stents? 6-month angiographic patency rate: 31.8% for AMS vs. 58.0% for PTA (p=0.013) Bosiers et al, CardiovascInterventRadiol 2009

  22. Take home messages • Primary stenting with self-expandable bare-metal stents is considered by many the standard of care for iliac and superficial femoral arteries • Bail-out drug-eluting stenting is beneficial for infra-popliteal lesions • Conversely, stents (any) should be avoided in common femoral or popliteal arteries • Further clinical evidence is needed before deciding on the role of absorbable stents and femoral drug-eluting stents

  23. Thank you for your attentionFor any correspondence: gbiondizoccai@gmail.comFor these and further slides on these topics feel free to visit the metcardio.org website:http://www.metcardio.org/slides.html

More Related